Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-986143 是一种口服有效的、可逆的BTK 抑制剂,IC50为 0.26 nM,具有自身免疫性疾病的研究潜力。BMS-986143 还抑制 TEC、BLK、BMX、TXK FGR、YES1、ITK,IC50分别为 3 nM、5 nM、7 nM、10 nM、15 nM、19 nM、21 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 10-14周 | ||
50 mg | ¥ 13,800 | 10-14周 | ||
100 mg | ¥ 17,500 | 10-14周 |
产品描述 | BMS-986143, an orally active, reversible BTK inhibitor with an IC50 value of 0.26 nM, is designed for autoimmune disease research. Additionally, it targets TEC, BLK, BMX, TXK, FGR, YES1, and ITK, exhibiting IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM, 19 nM, and 21 nM, respectively [1]. |
体外活性 | BMS-986143 inhibits BTK with IC 50 s of 6.9±3.4 and 25±19 nM in Ramos cellular assay and the human whole blood assay, respectively [1]. BMS-986143 can effectively inhibit the end-points derived from IgG-containing immune complex low affinity activating Fcγ receptor signaling in peripheral blood mononuclear cells (PBMC) (IC 50 =2 nM) [1]. BMS-986143 inhibits the expression of CD63 on the surface of basophils in human whole blood, driven by FcεRI signaling (IC 50 of 54 nM) [1]. BMS-986143 inhibits calcium flux in Ramos B Cells, proliferation of human peripheral B Cells, CD86 surface expression in peripheral B Cells, and TNFα from human PBMC Cells with IC 50 s of 7±3, 1±0.4, 1±0.5, and 2 nM, respectively [1]. |
体内活性 | BMS-986143 shows desirable efficacy in mouse models of collagen-induced arthritis (CIA) and anticollagen antibody-induced arthritis (CAIA) [1]. BMS-986143 exhibits high oral bioavailability (mouse 100%, dog 82%) and moderate C max (mouse 4.3, dog 1.2 μM) following oral administration (mouse 6, dog 2 mg/kg) [1]. BMS-986143 exhibits long elimination half-lives (mouse 3.6, dog 7.9 h) due to moderate plasma clearance (8.6, 4.4 mL/min/kg respectively) combined with low volumes of distribution (1.8, 2.6 L/kg respectively) following intravenous administration (mouse 3.0, dog 1.0 mg/kg) [1]. Animal Model: DBA/1 male mice (8-10wk of age) bearing CIA model [1] Dosage: 15 and 45 mg/kg Administration: Oral gavage; BID Result: 15 and 45 mg/kg provided dose-dependent inhibition of observed clinical disease progression (63% and 80%, respectively), representing 17 and 19 h coverage of the mouse whole blood IC 50 (130 nM). |
分子量 | 587.45 |
分子式 | C31H24Cl2N4O4 |
CAS No. | 1643372-95-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BMS-986143 1643372-95-5 BMS986143 BMS 986143 Inhibitor inhibitor inhibit